Details about Adrian Towse

Access statistics for papers by Adrian Towse.

Last updated 2025-07-06. Update your information in the RePEc Author Service.

Short-id: pto443

Working Papers

2022

1. Alternative funding models for medical innovation: the role of product development partnerships in product innovation for infectious diseases
   Post-Print, HAL
   See also Journal Article Alternative funding models for medical innovation: the role of product development partnerships in product innovation for infectious diseases, Applied Economics Letters, Taylor & Francis Journals (2023) (2023)
2. An Ambitious USG Advanced Commitment for Subscription-Based Purchasing of Novel Antimicrobials and Its Expected Return on Investment
   Policy Papers, Center for Global Development View citations (1)

2020

3. How Should the World Pay for a COVID-19 Vaccine?
   Monograph, Office of Health Economics View citations (2)

2019

4. Documento de debate sobre la fijación de precios en función de la indicación (IBP) ¿Deben variar los precios de los medicamentos según la indicación?
   Briefing, Office of Health Economics
5. Indication-Based Pricing (IBP) Discussion Paper: Should drug prices differ by indication?
   Briefing, Office of Health Economics
6. The Future of Global Health Procurement: Issues around Pricing Transparency
   Working Papers, Center for Global Development View citations (3)

2018

7. Multi-Indication Pricing (MIP): Practical Solutions and Steps to Move Forward
   Briefing, Office of Health Economics View citations (4)

2017

8. Antimicrobials Resistance: A Call for Multi-disciplinary Action. How Can HTA Help?
   Briefing, Office of Health Economics
9. Incentives for New Drugs to Tackle Anti-Microbial Resistance
   Briefing, Office of Health Economics View citations (2)

2016

10. How Can Health Technology Assessments in the Asia-Pacific Area Respond to Increased Clinical Uncertainty as a Consequence of Expedited US and EU Regulatory Processes?
    Briefing, Office of Health Economics

2015

11. Multi-indication Pricing: Pros, Cons and Applicability to the UK
    Seminar Briefing, Office of Health Economics View citations (6)

2014

12. Comparative and Relative Effectiveness: A Challenge For Health Systems, Regulators, or Pharmaceutical Companies?
    Occasional Paper, Office of Health Economics

2013

13. Critique of CHE Research Paper 81: Methods for the Estimation of the NICE Cost Effectiveness Threshold
    Occasional Paper, Office of Health Economics View citations (12)

2012

14. The Use of Pay-for-Performance for Drugs: Can It Improve Incentives for Innovation?
    Occasional Paper, Office of Health Economics View citations (3)
15. Value-Based Differential Pricing: Efficient Prices for Drugs in a Global Context
    NBER Working Papers, National Bureau of Economic Research, Inc View citations (6)
    See also Journal Article Value‐Based Differential Pricing: Efficient Prices for Drugs in a Global Context, Health Economics, John Wiley & Sons, Ltd. (2015) View citations (13) (2015)

2011

16. Pharmaceutical Pricing in Emerging Markets: Effects of Income, Competition and Procurement
    NBER Working Papers, National Bureau of Economic Research, Inc View citations (6)
    See also Journal Article Pharmaceutical Pricing in Emerging Markets: Effects of Income, Competition, and Procurement, Health Economics, John Wiley & Sons, Ltd. (2015) View citations (12) (2015)
17. Pharmaceutical Pricing in Europe: Is Differential Pricing a Win-Win Solution?
    Occasional Paper, Office of Health Economics View citations (2)

2010

18. New Drugs to Tackle Antimicrobial Resistance: EU Policy Options
    Occasional Paper, Office of Health Economics View citations (1)

2008

19. The Market for Biosimilars: Evolution and Policy Options
    Briefing, Office of Health Economics View citations (9)

2006

20. Three Challenges to Achieving Better Analysis for Better Decisions: Generalisability, Complexity and Thresholds
    Briefing, Office of Health Economics

2003

21. Reducing Harm to Patients in the National Health Service. Will the Government’s Compensation Proposals Help?
    Briefing, Office of Health Economics View citations (1)

1998

22. From Efficacy to Cost-Effectiveness
    Briefing, Office of Health Economics View citations (3)

1997

23. Regulating Prices Paid by the NHS for Medicines Supplied by the UK-Based Pharmaceutical Industry
    Briefing, Office of Health Economics View citations (2)

Journal Articles

2025

1. Pricing combination products: not how but who?
   The European Journal of Health Economics, 2025, 26, (4), 537-540

2023

2. Alternative funding models for medical innovation: the role of product development partnerships in product innovation for infectious diseases
   Applied Economics Letters, 2023, 30, (16), 2195-2199
   See also Working Paper Alternative funding models for medical innovation: the role of product development partnerships in product innovation for infectious diseases, Post-Print (2022) (2022)

2022

3. Supply-Side Cost-Effectiveness Thresholds: Questions for Evidence-Based Policy
   Applied Health Economics and Health Policy, 2022, 20, (5), 651-667 View citations (1)

2021

4. Health Opportunity Costs and Expert Elicitation: A Comment on Soares et al
   Medical Decision Making, 2021, 41, (3), 255-257 View citations (1)

2019

5. Advanced therapy medicinal products and health technology assessment principles and practices for value-based and sustainable healthcare
   The European Journal of Health Economics, 2019, 20, (3), 427-438 View citations (13)
6. Is rate of return pricing a useful approach when value-based pricing is not appropriate?
   The European Journal of Health Economics, 2019, 20, (7), 945-948 View citations (2)

2017

7. Time for a change in how new antibiotics are reimbursed: Development of an insurance framework for funding new antibiotics based on a policy of risk mitigation
   Health Policy, 2017, 121, (10), 1025-1030 View citations (8)

2016

8. Biosimilars: How Can Payers Get Long-Term Savings?
   PharmacoEconomics, 2016, 34, (6), 609-616 View citations (9)
9. Fostering incentives for research, development, and delivery of interventions for neglected tropical diseases: lessons from malaria
   Oxford Review of Economic Policy, 2016, 32, (1), 64-87

2015

10. European Union Pharmaceutical Markets: A Case for Differential Pricing?
    International Journal of the Economics of Business, 2015, 22, (2), 263-275 View citations (9)
11. Pharmaceutical Pricing in Emerging Markets: Effects of Income, Competition, and Procurement
    Health Economics, 2015, 24, (2), 238-252 View citations (12)
    See also Working Paper Pharmaceutical Pricing in Emerging Markets: Effects of Income, Competition and Procurement, NBER Working Papers (2011) View citations (6) (2011)
12. Value‐Based Differential Pricing: Efficient Prices for Drugs in a Global Context
    Health Economics, 2015, 24, (3), 294-301 View citations (13)
    See also Working Paper Value-Based Differential Pricing: Efficient Prices for Drugs in a Global Context, NBER Working Papers (2012) View citations (6) (2012)

2014

13. Orphan drugs policies: a suitable case for treatment
    The European Journal of Health Economics, 2014, 15, (4), 335-340 View citations (11)

2013

14. Operationalizing Value-Based Pricing of Medicines
    PharmacoEconomics, 2013, 31, (1), 1-10 View citations (15)

2012

15. Is it time to reconsider the role of patient co-payments for pharmaceuticals in Europe?
    The European Journal of Health Economics, 2012, 13, (1), 1-5 View citations (16)

2011

16. Incentives for R&D for New Antimicrobial Drugs
    International Journal of the Economics of Business, 2011, 18, (2), 331-350 View citations (1)

2007

17. If it ain't broke, don't price fix it: the OFT and the PPRS
    Health Economics, 2007, 16, (7), 653-665 View citations (8)

2006

18. The desirability and feasibility of economic studies of drugs post-launch
    The European Journal of Health Economics, 2006, 7, (1), 5-6 View citations (1)

2004

19. Genetic screening, health care and the insurance industry
    The European Journal of Health Economics, 2004, 5, (2), 116-121 View citations (3)

1999

20. Is disease management relevant in Europe: some evidence from the United Kingdom
    Health Policy, 1999, 48, (1), 69-77
21. Medical negligence and the NHS: an economic analysis
    Health Economics, 1999, 8, (2), 93-101 View citations (8)

1994

22. The Political Economy of Healthcare. By David Resisman. MacMillan Press, London, 1993. No. of pages: 267. ISBN: 0‐333‐58579‐8
    Health Economics, 1994, 3, (5), 347-348